Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Colonic microbiota fermentation to short-chain fatty acids refers to the metabolic activity by which the dense population of microorganisms residing in the colon ferment undigested carbohydrates and proteins that escape absorption in the small intestine. This anaerobic process produces **short-chain fatty acids** (SCFAs), primarily acetate, propionate, and butyrate, which account for 90–95% of total SCFAs present in the colon. These metabolites play crucial roles in shaping the gut environment by lowering pH, supporting energy metabolism for both host cells and other microbes, regulating immune responses—such as promoting regulatory T cell differentiation—and influencing systemic physiological processes including appetite control and energy homeostasis. The composition and function of colonic microbiota—and thus SCFA production—are strongly influenced by diet. While these processes have significant implications for health and disease states such as inflammation, metabolic syndrome, neurological disorders via gut-brain communication pathways, "colonic microbiota fermentation to short-chain fatty acids" is a **metabolic pathway**, not a single molecular therapeutic target like an enzyme or receptor. Because it describes a biological process rather than an individual molecule or receptor typically considered "druggable," it is **not classified as a canonical therapeutic target** under standard pharmacological definitions. There are no direct drugs targeting the process itself; some interventions like prebiotics/probiotics modulate this pathway indirectly. Drugs do not directly target this process; dietary interventions and microbiome modulators can influence it. SCFA levels in stool or blood may serve as biomarkers for colonic fermentation activity but are not specific molecular markers. No direct safety concerns related to targeting this process as a drug target; however, excessive protein fermentation can produce toxic metabolites such as ammonia and phenols.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Colonic microbiota fermentation to short-chain fatty acids.